Levetiracetam Stada

Levetiracetam, the active ingredient in Levetiracetam Stada, is an anticonvulsant presented as a tablet for oral use. It is indicated for the treatment of partial seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients diagnosed with epilepsy.

GNH USA supplies Levetiracetam Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable logistics for regulated markets. Products are shipped with full documentation, including certificates of analysis and import permits, to ensure seamless integration into national formularies.

Levetiracetam is an anticonvulsant used to control seizure activity in epilepsy.

Partial seizures: reduces the frequency and severity of focal onset seizures in patients with epilepsy. Generalized tonic‑clonic seizures: helps prevent convulsive episodes by stabilizing neuronal firing across both hemispheres. Myoclonic seizures: decreases sudden muscle jerks and improves control of myoclonic epilepsy. Adjunct therapy: can be combined with other antiepileptic drugs to enhance overall seizure control.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of lightheadedness or imbalance. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate cranial pain. - Irritability: mood changes or increased agitation. - Nausea: upset stomach or urge to vomit. - Coordination problems: clumsiness or difficulty with fine motor tasks.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood or behavior changes: depression, suicidal thoughts, or aggression. - Hematologic abnormalities: low blood cell counts such as neutropenia or thrombocytopenia. - Liver enzyme elevation: signs of hepatic dysfunction. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Blood disorders: severe anemia or pancytopenia.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal function: adjust dose in patients with impaired kidney function. - Psychiatric history: monitor for mood changes, especially in those with prior depression or anxiety. - Concomitant CNS depressants: use caution when combined with other sedating agents. - Pregnancy: evaluate risk‑benefit ratio as safety data are limited. - Driving and machinery: advise patients to assess personal response before operating vehicles or heavy equipment. - Alcohol consumption: discourage excessive intake as it may increase dizziness. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control. - Phenobarbital: can lower levetiracetam concentrations, potentially compromising effectiveness. - Phenytoin: may decrease levetiracetam levels.

Moderate Interactions (Monitor Closely): - Opioids: additive CNS depression may increase sedation or respiratory depression. - Fluoroquinolones: may enhance risk of CNS side effects such as dizziness or agitation. - Antidepressants (SSRIs): monitor for increased irritability or mood changes. - Antihistamines: may increase sedation. - Antihypertensives: observe for potential blood pressure changes.